<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fatma Dedeoglu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan Kim, MD, MMSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzanne C Li, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immunoglobulin A vasculitis (IgAV; formerly called Henoch-Schönlein purpura [HSP]) [<a href="#rid1">1,2</a>], is the most common form of systemic vasculitis in children, with an incidence range of 3 to 27 per 100,000 [<a href="#rid3">3</a>]. Ninety percent of cases occur in the pediatric age group. In contrast to many other forms of systemic vasculitis, IgAV is typically self-limited. The disease is characterized by a tetrad of clinical manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura in patients with neither thrombocytopenia nor coagulopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis/arthralgia</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney disease</p><p></p><p>The clinical manifestations, pathogenesis, diagnosis, and differential diagnosis of IgAV are presented here. The management of IgAV and a more complete discussion of the kidney manifestations of IgAV are found elsewhere. (See  <a class="medical medical_review" href="/d/html/6407.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Management"</a> and  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>IgAV is primarily a childhood disease that occurs between the ages of 3 and 15 years [<a href="#rid3">3,4</a>]. In a population-based study from the United Kingdom, the annual incidence was approximately 20 per 100,000 in children &lt;17 years of age, with a peak incidence of 70 per 100,000 in children between the ages of four and six years [<a href="#rid5">5</a>]. In reports from Taiwan and the Czech Republic, there was a lower incidence of 10 per 100,000 in children &lt;17 years of age, with a peak incidence at five to seven years of age [<a href="#rid6">6,7</a>]. A subsequent population-based study from France showed an incidence relatively similar to previously reported numbers (approximately 19 per 100,000 children), suggesting general stability of the incidence [<a href="#rid8">8</a>]. A higher incidence has been reported in several Asian studies, including a South Korean study that found an incidence of approximately 56 per 100,000 children [<a href="#rid9">9</a>]. Another South Korean observational study comparing two time periods (1987 to 1996 versus 2006 to 2015) found that the peak incidence was five years of age and also reported longer hospitalization and higher rate of proteinuria and recurrence in the earlier time period [<a href="#rid10">10</a>].</p><p>IgAV is less common in adults [<a href="#rid11">11</a>], with an estimated annual incidence of 5 per 100,000 adults in Slovenia [<a href="#rid12">12</a>]. In several retrospective studies, 20 to 30 percent of patients with IgAV were adults. In these cohorts, adults had significantly worse kidney outcomes compared with children [<a href="#rid13">13-15</a>].</p><p>Most studies show a male predominance, with reported male-to-female ratios of 1.2:1 to 1.8:1 [<a href="#rid3">3,5,6,12,16,17</a>], although two Korean studies have shown a slight female predominance [<a href="#rid9">9,18</a>]. IgAV is seen less frequently in Black British children compared with White or South Asian British children [<a href="#rid2">2,5</a>].</p><p>IgAV occurs primarily in the fall, winter, and spring but rarely in the summer months [<a href="#rid2">2,8,16-19</a>], possibly explained by the association of IgAV with infections. Approximately one-half of the cases of IgAV are preceded by an upper respiratory tract infection [<a href="#rid20">20</a>], especially those caused by <em>Streptococcus</em> [<a href="#rid21">21</a>]. Other infectious agents, vaccinations, and insect bites also have been implicated as possible triggers for IgAV [<a href="#rid20">20</a>]. A large epidemiologic study of 16,000 children from South Korea demonstrated a temporal relationship with respiratory syncytial virus (RSV), influenza, and norovirus [<a href="#rid18">18</a>]. In a systematic literature review, it was noted that a majority of the studies had failed to show causal association between vaccinations and vasculitides including IgAV [<a href="#rid22">22-24</a>]. The rate of IgAV is significantly higher (approximately 5 percent) in patients with familial Mediterranean fever [<a href="#rid25">25,26</a>]. In addition, MEFV innate immunity regular, pyrin (<em>MEFV</em>) pathogenic variants may affect clinical presentation of IgAV. Abdominal pain and intussusception were more common in patients with <em>MEFV</em> pathogenic variants [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H324266508"><span class="h1">CLASSIFICATION CRITERIA</span><span class="headingEndMark"> — </span>A variety of classification criteria for IgAV have been proposed, primarily for use in research protocols and outcome studies. They have not been validated for the diagnosis of individual cases.</p><p>In 1990, a committee of the American College of Rheumatology (ACR) established criteria to classify seven types of vasculitides including IgAV [<a href="#rid28">28,29</a>]. The ACR criteria for the diagnosis of IgAV are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura</p><p class="bulletIndent1"><span class="glyph">●</span>Age at onset ≤20 years</p><p class="bulletIndent1"><span class="glyph">●</span>Acute abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy showing granulocytes in the walls of small arterioles and/or venules</p><p></p><p>These criteria were based upon a comparison between 85 patients with IgAV and 722 adult patients with other forms of vasculitis. Two or more of the criteria had a sensitivity and specificity of approximately 90 percent in separating adult patients with IgAV from those with other causes of vasculitis.</p><p>In 2005, pediatric consensus criteria were developed by the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) and the Paediatric Rheumatology European Society (PRES) [<a href="#rid30">30</a>] and were subsequently validated in conjunction with the Paediatric Rheumatology International Trials Organisation (PRINTO) [<a href="#rid31">31</a>]. These criteria, which have a 93 percent sensitivity and 89 percent specificity, are more appropriate for pediatric settings in which a clinician is most likely seeking features to distinguish IgAV from gastroenteritis or appendicitis rather than from granulomatosis with polyangiitis. The mandatory criterion is purpura (usually palpable and in clusters) or petechiae, with lower limb predominance and without thrombocytopenia or coagulopathy. Patients also must have one or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain (usually diffuse, with acute onset)</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis or arthralgia (acute onset)</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney involvement (proteinuria, hematuria)</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclastic vasculitis or proliferative glomerulonephritis, with predominant IgA deposition</p><p></p><p>However, IgAV is not the only disease that may have these manifestations. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>IgAV is an immune-mediated vasculitis associated with IgA deposition accompanied with complement deposition and neutrophil recruitment. Although a variety of infectious and chemical triggers are recognized, the underlying cause of IgAV remains unknown. Immunologic, genetic, and environmental factors all seem to play a role [<a href="#rid32">32-34</a>]. The human leukocyte antigen (HLA) region as well as polymorphisms in other immune-related genes are associated with IgAV, sometimes with conflicting results, which could be due to differences in ethnic and environmental factors [<a href="#rid35">35,36</a>]. Susceptibility polymorphisms in genes that are associated with vascular response, such as the genes encoding endothelial nitric oxide synthase (eNOS), interleukin (IL) 18, and angiotensin-converting enzyme (ACE), have also been shown [<a href="#rid2">2,37</a>]. There are numerous case reports of IgAV occurring after vaccination, and a case-control study found an increased risk of IgAV within 12 weeks after vaccination with the measles-mumps-rubella (MMR) vaccine (odds ratio [OR] 3.4, 95% CI 1.2–10.0) but not with other vaccines [<a href="#rid38">38</a>]. The absolute risk was low, though (2.8 percent of cases had MMR within 12 weeks of developing IgAV compared with 1 percent of controls). A case-crossover study of 167 children found no increased risk of IgAV within three months of receiving a vaccine compared with the three months prior to that (OR 1.6, 95% CI 0.8-3.0) [<a href="#rid24">24</a>]. Similar results were seen for IgAV risk within 1, 1.5, or 2 months of vaccination. These results suggest that vaccinations are not a major etiologic factor in IgAV and therefore should not be avoided. A temporal relationship of IgAV with administration of many classes of drugs including biologics has been reported [<a href="#rid39">39,40</a>].</p><p>The characteristic finding of IgAV is leukocytoclastic vasculitis accompanied by IgA immune complexes within affected organs  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/d/graphic/52548.html" rel="external">image 1A-B</a>). Skin biopsies of purpuric lesions demonstrate the involvement of small vessels (primarily postcapillary venules) within the papillary dermis. The predominant cell types within the inflammatory infiltrate are neutrophils and monocytes. (See <a class="local">'Biopsy'</a> below.)</p><p>Immunofluorescence studies show IgA, complement component 3 (C3), and fibrin deposition within the walls of involved vessels. IgA, C3, fibrin, immunoglobulin G (IgG), and, less commonly, immunoglobulin M (IgM) also are deposited within the endothelial and mesangial cells of the kidney  (<a class="graphic graphic_picture graphicRef69895" href="/d/graphic/69895.html" rel="external">picture 1</a>).</p><p>Attention has focused on the potential role of increased serum levels of IgA and IgA immune complexes in the pathogenesis of IgAV, which contributed the current name change. In addition, several studies report alterations in the glycosylation of IgA, elevated levels of IgA anticardiolipin antibodies, and increased levels of transforming growth factor (TGF) beta in patients with IgAV [<a href="#rid17">17,41-45</a>]. The fact that only one of the two IgA subtypes (galactose-deficient IgA1, but not IgA2) is found in the inflammatory infiltrates of this disease remains unexplained [<a href="#rid46">46,47</a>]. Galactose-deficient IgA1 containing immune complexes may deposit more easily [<a href="#rid3">3</a>]. Similarly, the precise role of IgA and the specific involvement of IgA1 in the pathogenesis of IgAV remain unclear. Some research suggests that IgA anticardiolipin antibodies may play a role [<a href="#rid41">41,48,49</a>]. Results from one study suggest that beta-2-glycoprotein I (beta-2GPI) is an antigenic target for IgA [<a href="#rid50">50</a>]. Despite the increased presence of these antibodies, there are few reports of thrombosis. Activated neutrophils and increased production of IL-8, as well as activated cytotoxic T cells and natural killer (NK) cells, may also play a role [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS IN CHILDREN</span><span class="headingEndMark"> — </span>The classic tetrad of IgAV includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpable purpura without thrombocytopenia and coagulopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Arthritis/arthralgia</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Kidney disease</p><p></p><p>These clinical manifestations may develop over the course of days to weeks and may vary in their order of presentation. Purpura and joint pain are usually the presenting symptoms, but this is not always the case. In the absence of the classic purpuric rash, the diagnosis of IgAV may not be obvious. Patients who present with significant joint or abdominal symptoms without the skin manifestations may be thought to have an infectious or surgical process. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>The mean age of onset of IgAV is between six and seven years. Based upon retrospective reviews from several different countries, the major clinical manifestations develop with the following frequencies [<a href="#rid5">5,6,13,14,16,17,53-57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Purpura – Purpura is the presenting symptom in approximately three-quarters of patients, preceding other symptoms by a mean of four days in one series [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arthralgia/arthritis – In most of the series, joint symptoms were the second most common manifestation, occurring in slightly over one-half to three-quarters of the patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain – Colicky pain occurred in approximately one-half of patients and gastrointestinal bleeding in approximately 20 to 30 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Kidney disease – The frequency of kidney involvement ranged from 21 to 54 percent.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Skin manifestations</span><span class="headingEndMark"> — </span>Rash is the presenting sign in approximately three-quarters of patients. The rash often begins with erythematous, macular, or urticarial wheals but also can have less typical presentations including targetoid lesions. The rash may be itchy but is rarely painful. The initial rash may coalesce and evolve into the typical ecchymoses, petechiae, and palpable purpura  (<a class="graphic graphic_picture graphicRef100110 graphicRef119923 graphicRef134597 graphicRef134598 graphicRef134599" href="/d/graphic/100110.html" rel="external">picture 2A-E</a>). The rash typically appears in crops, symmetrically distributed, and located primarily in gravity/pressure-dependent areas, such as the lower extremities. The buttocks are often involved in toddlers and the face, trunk, and upper extremities in nonambulatory children [<a href="#rid2">2,3</a>].</p><p>Localized subcutaneous edema is a common feature that may be found in dependent and periorbital areas, especially in younger children (less than three years of age)  (<a class="graphic graphic_picture graphicRef100112" href="/d/graphic/100112.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef98550" href="/d/graphic/98550.html" rel="external">picture 4</a>). Even adult patients, however, may also have this manifestation of IgAV, particularly involving the dorsal aspect of the hands. Blistering eruptions may also occur [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Arthritis/arthralgia</span><span class="headingEndMark"> — </span>Arthritis/arthralgia occur in up to 84 percent of patients [<a href="#rid16">16,56</a>]. However, joint complaints are uncommon as the sole symptom at presentation and are the presenting symptom in approximately 15 percent of patients.</p><p>The arthritis is usually transient or migratory, typically oligoarticular (one to four joints), and nondeforming. It usually affects the lower-extremity large joints (hips, knees, and ankles) or less commonly the upper extremities (elbows, wrists, and hands) [<a href="#rid2">2,3,16,17,53</a>]. There is often prominent periarticular swelling and tenderness but usually without joint effusion, erythema, or warmth. Patients may have considerable pain and limitation of motion. Younger children with lower-extremity involvement may refuse to ambulate. The arthritis does not cause any chronic damage or sequelae. It may precede the appearance of purpura, though usually by no more than one or two days.</p><p class="headingAnchor" id="H7"><span class="h2">Gastrointestinal symptoms</span><span class="headingEndMark"> — </span>Gastrointestinal symptoms occur in approximately one-half of children with IgAV and range from mild (nausea, vomiting, abdominal pain, and transient paralytic ileus) to more significant findings (gastrointestinal hemorrhage, bowel ischemia and necrosis, intussusception, and bowel perforation). Guaiac-positive stool is found in up to 56 percent of patients, but massive gastrointestinal hemorrhage is rare [<a href="#rid60">60</a>]. The frequent presence of fecal occult blood, increased stool alpha-1-antitrypsin, and hypoalbuminemia without proteinuria, even in patients without gastrointestinal symptoms, suggests that gastrointestinal involvement and mucosal injury are more common than the clinical history indicates [<a href="#rid58">58</a>].</p><p>Gastrointestinal symptoms typically develop within eight days of the appearance of the rash, although much longer intervals (weeks to months) have been described [<a href="#rid61">61</a>]. Gastrointestinal complaints precede the rash in approximately 15 to 35 percent of cases. In such patients, the diagnosis of IgAV is significantly more difficult. Gastrointestinal symptoms without the appearance of cutaneous purpura at any time also have been described in case reports [<a href="#rid62">62-64</a>]. In one small, retrospective review of children who had skin biopsies, edema and rash above the waist were most common in patients who presented with gastrointestinal involvement [<a href="#rid65">65</a>]. The reason for such a putative association is not clear<em>, </em>since the rash of IgAV is typically found in gravity/pressure-dependent areas. This finding will require confirmation in a larger cohort before it can be relied upon. In a meta-analysis, high neutrophil-to-lymphocyte ratio (NLR) and low mean platelet volume (MPV) were predictors of severe gastrointestinal involvement, though there was significant heterogeneity among studies that were from only a few regions (China, Turkey, and South Korea), limiting the generalizability of these findings [<a href="#rid66">66</a>].</p><p>Gastrointestinal pain associated with IgAV is caused by submucosal hemorrhage and edema. Purpuric lesions may be seen on endoscopy, commonly in the descending duodenum, stomach, and colon. The terminal ileum also may be involved. Submucosal edema, ulceration, and spasm of the ileum and jejunum may be seen in small bowel series. (See  <a class="medical medical_review" href="/d/html/8229.html" rel="external">"Overview of gastrointestinal manifestations of vasculitis"</a>.)</p><p>Intussusception is the most common gastrointestinal complication of IgAV. Rarer gastrointestinal manifestations include acute pancreatitis, gall bladder involvement, bowel perforation, and, in children, protein-losing enteropathy [<a href="#rid60">60,67-72</a>].</p><p>Edema and hemorrhage can act as a pathologic lead point, contributing to the development of intussusception. Intussusception is limited to the small bowel in approximately 60 percent of cases, in contrast to idiopathic intussusception, which is typically ileocolic [<a href="#rid73">73</a>]. Intussusception in IgAV has a reported overall incidence of 2.3 to 3.5 percent, although some retrospective series reported an incidence of only 0.4 to 0.6 percent [<a href="#rid16">16,53,60</a>]. This discrepancy may be due to differences in the population studied. Children demonstrating severe gastrointestinal pain and/or requiring hospitalization are presumably at greater risk.</p><p>In a retrospective review of 149 hospitalized children with IgAV from two centers in Chicago, 63 patients (42 percent) presented with severe abdominal pain [<a href="#rid74">74</a>]. Four patients were diagnosed with intussusception, two of which were ileoileal intussusceptions. All four patients required surgical correction. Intussusception is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5898.html" rel="external">"Intussusception in children"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>The kidney manifestations of IgAV, including prognosis and treatment, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a>.)</p><p>Kidney involvement has been reported in 20 to 54 percent of children with IgAV. It is more prevalent in older children and adults [<a href="#rid53">53,55</a>]. The most common presentation is hematuria with or without red blood cell casts and mild or no proteinuria. Nephrotic-range proteinuria, an elevated serum creatinine, and/or hypertension are present in a minority of patients. These findings, as well as the coexistence of hematuria and proteinuria, are associated with an increased risk of progressive disease, which occurs more frequently in adults. The findings on kidney biopsy are identical to those in IgA nephropathy. The presence of microscopic papillary dermal edema and perivascular deposition of C3 on direct immunofluorescence of skin biopsy samples may be associated with development of kidney involvement [<a href="#rid65">65</a>].</p><p>Risk factors predicting kidney involvement are not well known, but several clinical and laboratory features have been reported as kidney disease risk factors. In one meta-analysis, older age at onset; gastrointestinal symptoms; relapse; elevated white blood cell count, platelet count, and antistreptolysin O (ASLO) titer; and low C3 were reported as kidney disease risk factors, and a scoring system for risk of kidney disease development was suggested [<a href="#rid75">75</a>]. Other findings associated with development of severe kidney disease include delay in diagnosis, angioedema, central nervous system (CNS) involvement, and persistent purpura [<a href="#rid76">76,77</a>]. Long-term follow-up of these patients is important to determine which patients go on to develop end-stage kidney disease (ESKD), thus identifying which of the kidney risk factors are actually associated with ESKD.</p><p class="headingAnchor" id="H10"><span class="h2">Other organ involvement</span><span class="headingEndMark"> — </span>Other organ systems occasionally are involved in IgAV.</p><p class="headingAnchor" id="H37580706"><span class="h3">Urologic</span><span class="headingEndMark"> — </span>Urologic involvement, most commonly of the scrotum, but also the ureter, bladder, prostate, testicle, and penis, is reported [<a href="#rid78">78</a>]. The rate of scrotal involvement in boys with IgAV ranges from 2 to 38 percent [<a href="#rid79">79-82</a>]. Rarely, scrotal pain may be the presenting symptom. Clinical findings include pain, tenderness, and swelling of the involved testicle and/or scrotum.</p><p>The presentation may mimic testicular torsion [<a href="#rid83">83</a>]. Evaluation including ultrasonography and technetium Tc99m radionuclide scanning can differentiate the two entities. In testicular torsion, these studies demonstrate decreased blood flow to the testicle, in contrast to the normal or increased flow seen in boys with IgAV.</p><p>The clinical presentation of scrotal involvement in IgAV was reviewed in a retrospective study of 120 Korean boys diagnosed with IgAV between 1992 and 2004 [<a href="#rid84">84</a>]. Twenty-six patients (22 percent) had scrotal involvement, which presented as scrotal swelling (23 patients) or scrotal pain or tenderness (18 patients). Unilateral involvement was more common, with seven patients demonstrating inflammation of the scrotum bilaterally (27 percent). Scrotal pain was the initial manifestation of IgAV in two of the patients. Imaging (ultrasonography and/or radionuclide scan) was performed in 15 patients and demonstrated epididymitis in 13 and orchitis in 2 patients. One patient underwent surgical exploration, but there was no evidence of testicular torsion.</p><p class="headingAnchor" id="H37580713"><span class="h3">Central and peripheral nervous system</span><span class="headingEndMark"> — </span>Single reports and case series document neurologic manifestations in children with IgAV including headaches, seizures, encephalopathy (both hypertensive encephalopathy and posterior reversible encephalopathy syndrome [PRES]), focal neurologic deficits, ataxia, intracerebral hemorrhage, and central and peripheral neuropathy [<a href="#rid85">85-88</a>]. Most of the CNS findings are transient except for occasional permanent sequelae associated with hemorrhagic stroke.</p><p class="headingAnchor" id="H37580720"><span class="h3">Respiratory tract</span><span class="headingEndMark"> — </span>In a cohort of French patients hospitalized for IgAV, impaired lung diffusion capacity and mild interstitial changes on chest radiographs were found in the majority of patients (97 and 69 percent, respectively), despite the absence of significant respiratory symptoms [<a href="#rid89">89</a>]. Similarly, another study found impaired lung diffusion capacity in IgAV patients who did not have clinical or radiologic evidence of lung involvement compared with age-matched control patients [<a href="#rid90">90</a>]. On the other hand, severe lung involvement, such as pulmonary hemorrhage, is rare in patients with IgAV and is primarily reported in adults and adolescents [<a href="#rid91">91-94</a>]. A comprehensive, 40-year review of lung involvement in IgAV found diffuse alveolar hemorrhage was the most frequent presentation [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H37580808"><span class="h3">Eyes</span><span class="headingEndMark"> — </span>Keratitis and uveitis are rare sequelae of IgAV and usually suggest other diseases [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/6900.html" rel="external">"The red eye: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">CLINICAL MANIFESTATIONS IN ADULTS</span><span class="headingEndMark"> — </span>Adult patients with IgAV present with clinical manifestations similar to those that occur in children [<a href="#rid97">97</a>]. There are two main differences between adults and children with IgAV:</p><p class="bulletIndent1"><span class="glyph">●</span>Intussusception is rare in adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults are at increased risk for developing significant kidney involvement including end-stage kidney disease (ESKD) [<a href="#rid11">11,14,98-102</a>]. (See <a class="local">'Kidney disease'</a> above.)</p><p></p><p>These characteristics of IgAV in adults were best illustrated in a retrospective review of 250 French patients whose median age was 50 years. At presentation, clinical findings included palpable purpura (96 percent), arthritis (61 percent), and gastrointestinal symptoms (48 percent) [<a href="#rid98">98</a>]. Almost one-third of patients had kidney insufficiency (creatinine clearance &lt;50 mL/minute per m<sup>2</sup>) within four months of presentation. At a median follow-up of 14.8 years, persistent kidney impairment was seen in 80 patients (32 percent of the original cohort), including ESKD in 27 patients and severe kidney impairment (creatinine clearance &lt;30 mL/minute) in another 32 patients. Potential explanations for the high prevalence of substantial kidney impairment in this study include the possibility of selection bias (all patients in the study had kidney disease severe enough to require kidney biopsy), the long period of follow-up compared with other studies, and the possible role of comorbidities (eg, hypertension) contributing to the progression of kidney disease. An updated report on this cohort that included an additional 10 patients revealed similar results [<a href="#rid99">99</a>]. However, a smaller case series of adult patients from Northern India showed greater rates of arthritis (90 percent) and abdominal pain in only 10 percent of adults at presentation [<a href="#rid103">103</a>], which may suggest differences related to genetic and environmental exposures between these countries. Reported outcomes are worse in adult patients &gt;65 years of age compared with other adults: Older patients achieved clinical remission less often (23.9 versus 46.2 percent) and developed a 50 percent increase in their serum creatinine more often during the period of observation (21.7 versus 4.7 percent) [<a href="#rid101">101</a>]. Another retrospective cohort study comparing 35 adults to 159 children with IgAV also found kidney involvement to be more common in adults. Upper respiratory infections were a frequent trigger for both groups. Nonsteroidal antiinflammatory drugs (NSAIDs) were used more often in children, while adults were typically treated with glucocorticoids and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. Persistent hematuria was found to be independent risk factor for relapse in both groups and was more common in adults [<a href="#rid15">15</a>].</p><p>Another retrospective series reviewed 68 adults with IgAV who had a skin biopsy with leukocytoclastic vasculitis on histopathologic evaluation and IgA on direct immunofluorescence. Notable findings in this patient group included a higher rate of kidney involvement in patients older than 40 years whose skin biopsies showed an absence of eosinophils and a higher rate of gastrointestinal involvement in patients whose biopsies showed an absence of histiocytes [<a href="#rid104">104</a>].</p><p>Adults with no known trigger for the development of IgAV should have additional evaluation for solid-organ cancers, especially if the disease is prolonged or recalcitrant to treatment [<a href="#rid105">105</a>].</p><p>A more complete discussion of the kidney manifestations and the management of kidney disease in patients with IgAV is found separately. (See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a>.)</p><p class="headingAnchor" id="H26234283"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>Serum IgA levels have been reported to be elevated in 50 to 70 percent of patients with IgAV, and higher levels are associated with kidney involvement [<a href="#rid17">17,42,106</a>].</p><p>Findings on routine blood tests (eg, complete blood cell count, serum chemistries, and urinalysis) are nonspecific. Patients may have a normochromic anemia because of occult or overt gastrointestinal bleeding. Other results, such as markers of inflammation, generally reflect the triggering condition. IgAV following bacterial infections is more likely to be characterized by leukocytosis (white blood cell count &gt;20,000 cells/mm<sup>3</sup>) and an elevated erythrocyte sedimentation rate (ESR). IgAV after viral illnesses, on the other hand, often fails to demonstrate elevation of acute-phase reactants. Nevertheless, IgAV generally does not cause systemic inflammation; as such, when present, other etiologies mimicking IgAV should be considered (see <a class="local">'Differential diagnosis'</a> below). Prothrombin time (PT), partial thromboplastin time (PTT), bleeding time, and platelet count are usually all normal. The initial urinalysis is also typically normal, although proteinuria and/or hematuria may develop over time.</p><p>Hypocomplementemia is reported in a significant percentage of children with IgAV, and these patients are more likely to have evidence of a recent streptococcal infection [<a href="#rid107">107</a>]. A case series of 338 children hospitalized at one center in China during a six-month period in 2010 to 2011 found that 53 children (15.7 percent) had decreased levels of complement component 3 (C3) and/or complement component 4 (C4). Complement levels normalized within three months in all patients, and they did not correlate with disease severity or presence of nephritis in this cohort. As noted previously, several reports and a meta-analysis suggest neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV) may be predictors of severe gastrointestinal involvement [<a href="#rid66">66</a>]. Additional studies with larger cohorts are needed to confirm these findings.</p><p class="headingAnchor" id="H13"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of IgAV is typically based upon clinical manifestations of the disease (palpable purpura without thrombocytopenia or coagulopathy and two or three of the remaining clinical features: arthritis/arthralgia, abdominal pain, and kidney disease) [<a href="#rid2">2,3,108,109</a>]. The diagnosis is straightforward when patients present with the classic signs and symptoms (palpable purpura of the lower extremities and buttocks in combination with two or more of the other typical disease manifestations). However, the classic rash of IgAV is not the initial presenting sign in approximately one-quarter of affected persons. It may be difficult to make the diagnosis of IgAV prior to the appearance of a rash in patients who present with other clinical manifestations, such as abdominal pain or arthritis, particularly in isolation. In patients with incomplete or unusual presentations, a biopsy of an affected organ (eg, skin or kidney) that demonstrates leukocytoclastic vasculitis with a predominance of IgA deposition confirms the diagnosis of IgAV. The diagnostic approach is reviewed in the algorithm  (<a class="graphic graphic_algorithm graphicRef140304" href="/d/graphic/140304.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H14"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>In pediatric patients, biopsy is reserved for patients with an unusual presentation of IgAV (ie, no rash, or an atypical rash) or those with significant kidney disease.</p><p>Confirmation of the diagnosis by biopsy is more important in adult patients because of the lower incidence of IgAV beyond the pediatric age group and the comparatively higher incidence of other forms of vasculitis that may be clinically similar to IgAV.</p><p class="headingAnchor" id="H15"><span class="h3">Skin</span><span class="headingEndMark"> — </span>Biopsies of the skin, which sample the small blood vessels of the superficial dermis, are usually adequate to make the diagnosis of IgAV. Light microscopy studies (hematoxylin and eosin stains) demonstrate the classical leukocytoclastic vasculitis in postcapillary venules with IgA deposition that is pathognomonic of IgAV  (<a class="graphic graphic_diagnosticimage graphicRef52548 graphicRef66296" href="/d/graphic/52548.html" rel="external">image 1A-B</a>) [<a href="#rid110">110</a>]. The biopsy should contain skin lesions that are less than 24 hours old because, in more chronic lesions, vessel damage leads to nonspecific leakage of all isotypes of immunoglobulin. Immunofluorescence studies, essential to confirming the diagnosis of IgAV, generally require biopsy of a second skin site.</p><p class="headingAnchor" id="H16"><span class="h3">Kidney</span><span class="headingEndMark"> — </span>Kidney biopsy is reserved for patients in whom the diagnosis is uncertain or if there is clinical evidence of severe kidney involvement. IgAV is characterized by IgA deposition in the mesangium on immunofluorescence microscopy that is identical to that in IgA nephropathy  (<a class="graphic graphic_picture graphicRef69895" href="/d/graphic/69895.html" rel="external">picture 1</a>). Light microscopy changes range from isolated mesangial proliferation to severe crescentic glomerulonephritis. (See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>No laboratory test is diagnostic for IgAV. However, confirmation of a normal platelet count and coagulation studies (prothrombin time [PT], partial thromboplastin time [PTT], and bleeding time) are necessary when clinical features do not allow conclusive distinction of IgAV from other diseases that present with purpura due to thrombocytopenia or coagulopathy. Other studies may be performed as part of the evaluation for disorders in the differential diagnosis. Some laboratory studies, such as urinalysis, are obtained once the diagnosis of IgAV is made but are not required for diagnosis. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/6443.html" rel="external">"Purpuric skin lesions (petechiae, purpura, and ecchymoses) in children: Evaluation"</a> and <a class="local">'Additional evaluation'</a> below.)</p><p>In patients who have an atypical presentation, such as abdominal pain before or without the rash, endoscopy (EGD) or video capsule endoscopy (VCE) may be needed to confirm the diagnosis. One study of 30 children in whom the diagnosis was still under question even after standard EGD described VCE findings of IgAV (eg, mucosal erosion, erythema, and/or petechia) in most patients [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>In children presenting with the classic signs of palpable purpura plus some combination of abdominal pain, arthritis/arthralgia, and/or kidney involvement, the diagnosis of IgAV is generally straightforward [<a href="#rid30">30</a>]. However, the diagnosis is more difficult if there is an incomplete presentation of IgAV, particularly if the skin manifestations are initially absent. In these circumstances, other causes for purpura, arthritis, abdominal pain, and kidney disease need to be considered [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Purpura</span><span class="headingEndMark"> — </span>Petechiae and purpuric rashes may be associated with septicemia, immune thrombocytopenia (ITP), hemolytic uremic syndrome, leukemia, and coagulopathies (eg, hemophilia). Normal platelet count and coagulation studies differentiate IgAV from these entities.</p><p>However, there are several other conditions that may present with purpura with normal platelet counts and coagulation studies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute hemorrhagic edema of infancy (AHEI)</strong> – AHEI (also known as Finkelstein or Seidlmayer disease) is a leukocytoclastic vasculitis described in children between the ages of four months to two years [<a href="#rid112">112-116</a>]. It is a self-limited disease that presents with fever, purpura, ecchymosis, and inflammatory edema of the limbs and resolves in one to three weeks  (<a class="graphic graphic_picture graphicRef100111" href="/d/graphic/100111.html" rel="external">picture 5</a>). Involvement of the kidney and the gastrointestinal tract is uncommon, but, when it occurs, it is very similar to that seen in IgAV [<a href="#rid117">117,118</a>]. Biopsy of the skin demonstrates a leukocytoclastic vasculitis with occasional IgA deposition. It is unclear whether this condition is truly a separate entity from IgAV or actually overlaps with it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity vasculitis</strong> – Hypersensitivity vasculitis is an inflammation of the small vessels that occurs after exposure to drugs or infection or without an identifiable trigger [<a href="#rid29">29</a>]. Patients present with fever, urticaria, lymphadenopathy, and arthralgias but not usually glomerulonephritis. Histopathology shows a leukocytoclastic vasculitis primarily of the postcapillary venules, but IgA deposition is absent. (See  <a class="medical medical_review" href="/d/html/6404.html" rel="external">"Hypersensitivity vasculitis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other small vessel vasculitides</strong> – There are a number of causes of small vessel vasculitis (including IgAV) that may present with asymmetric polyneuropathy, palpable purpura, and/or pulmonary or kidney involvement. These diseases include primary vasculitides (eg, granulomatosis with polyangiitis), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), and vascular inflammation secondary to a connective tissue disorder (eg, systemic lupus erythematosus [SLE]) or to an infectious disease (eg, hepatitis B or C). In general, these diseases are uncommon in children. (See  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a> and  <a class="medical medical_review" href="/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a>.)</p><p></p><p>Laboratory evaluation of autoantibodies, including antinuclear antibodies, anti-double-stranded DNA (anti-dsDNA), and antineutrophil cytoplasmic antibodies (ANCAs), is typically negative in IgAV. Abnormal results for any of these studies may differentiate IgAV from the other causes of small vessel vasculitis. The majority of patients have normal complement levels, but hypocomplementemia has been reported both in IgAV and in AHEI [<a href="#rid117">117</a>]. Light microscopic examination of a purpuric lesion demonstrates leukocytoclasis in many small vessel vasculitides, but it is the predominance of IgA deposition that distinctively characterizes IgAV. (See  <a class="medical medical_review" href="/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification"</a> and  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Small-vessel vasculitis'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Arthritis and arthralgia</span><span class="headingEndMark"> — </span>In approximately 15 percent of patients with IgAV, arthritis or arthralgia may be the presenting manifestation, usually preceding the skin manifestations by only one day. Until a patient develops the classical purpura of IgAV, other causes of joint complaints must be considered including autoimmune diseases, septic or reactive arthritis, and toxic synovitis (also called transient synovitis).</p><p>Autoimmune diseases, such as SLE, juvenile idiopathic arthritis (JIA), and rheumatic fever, may present with joint symptoms similar to IgAV. Assays for serum complement, antinuclear and anti-dsDNA antibodies, and rheumatoid factor are typically normal in patients with IgAV. Abnormal results for any of these studies may help to differentiate IgAV from SLE and JIA, although at least 15 percent of patients with IgAV may also have transient hypocomplementemia [<a href="#rid107">107</a>].</p><p>Evidence of a recent group A beta-hemolytic streptococci infection (eg, positive throat culture, positive rapid streptococcal antigen test, or elevated anti-streptolysin O [ASLO] titers) and the clinical course distinguish acute rheumatic fever from IgAV, with the caveat that a significant proportion of cases of IgAV are triggered by streptococcal infections. Reactive arthritis may be triggered by a variety of genitourinary and gastrointestinal pathogens including beta-hemolytic streptococcal infections. Reactive arthritis may cause a painful polyarthritis and high fevers, but the characteristic rash of IgAV should allow distinction between these conditions. Similarly, when considering toxic synovitis, another self-limited disease with transient joint findings that resolve without long-term sequelae, evolution of the other manifestations of IgAV will help differentiate the two conditions. (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6414.html" rel="external">"Polyarticular juvenile idiopathic arthritis: Clinical manifestations, diagnosis, and complications"</a> and  <a class="medical medical_review" href="/d/html/6415.html" rel="external">"Oligoarticular juvenile idiopathic arthritis"</a> and  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis"</a>.)</p><p>Septic arthritis and toxic synovitis also may present with joint symptoms similar to those seen in patients with IgAV. Septic arthritis and toxic synovitis also may present with joint symptoms similar to those seen in patients with IgAV. These typically involve only one joint, unlike the oligoarthritis involving several joints seen in IgAV. Additionally, affected joints are warm and erythematous in septic arthritis, unlike those in IgAV. In most circumstances, these conditions are easily distinguished from IgAV by an experienced clinician. However, joint aspiration may be needed to differentiate the two. (See  <a class="medical medical_review" href="/d/html/6030.html" rel="external">"Bacterial arthritis: Clinical features and diagnosis in infants and children", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/2856.html" rel="external">"Approach to hip pain in childhood", section on 'Common causes of hip pain in children'</a> and  <a class="medical medical_review" href="/d/html/6460.html" rel="external">"Overview of the causes of limp in children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Abdominal pain</span><span class="headingEndMark"> — </span>Distinguishing acute abdominal emergencies, such as appendicitis, from IgAV may be difficult before purpura develops. Although the rash of IgAV usually precedes gastrointestinal manifestations and seldom lags by more than a few days, evaluation for potential acute abdomen cannot be delayed. In addition, the IgAV rash may be a nonspecific erythematous or urticarial exanthem or limited to lesions on the buttocks or lower extremities early in the disease course. Thus, careful serial examinations of the entire child are essential when considering the diagnosis. Radiologic studies used to screen for surgical causes of abdominal pain are also used in patients with IgAV who develop gastrointestinal complications, such as intussusception, bowel infarction, or perforation. (See  <a class="medical medical_review" href="/d/html/6454.html" rel="external">"Causes of acute abdominal pain in children and adolescents"</a> and <a class="local">'Imaging studies'</a> below.)</p><p class="headingAnchor" id="H24"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Patients with IgA nephropathy present with immunologic and histopathologic findings similar to those of patients with IgAV. As is true of patients with IgAV, manifestations of IgA nephropathy vary from microscopic hematuria to acute kidney injury. Although patients with IgA nephropathy do not have the other clinical characteristics of IgAV, these two entities may share a similar pathogenesis. (See  <a class="medical medical_review" href="/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H26234496"><span class="h1">ADDITIONAL EVALUATION</span><span class="headingEndMark"> — </span>Additional studies that are frequently performed upon diagnosis as part of the initial evaluation include urinalysis in all patients and imaging studies in those with significant gastrointestinal symptoms.</p><p class="headingAnchor" id="H26234502"><span class="h2">Kidney studies</span><span class="headingEndMark"> — </span>Urinalysis should be performed in all patients with IgAV to screen for evidence of kidney involvement. In general, findings on urinalysis reflect the degree of kidney injury and may include the presence of red or white blood cells, cellular casts, and proteinuria. Serum creatinine should be obtained in all adult patients with IgAV because of the increased risk of significant kidney disease. Kidney disease is less prevalent in children, so serum creatinine need not be obtained unless the patient is hypertensive or has abnormalities on the urinalysis. Kidney involvement often becomes detectable after other manifestations of IgAV, so urinary screening should be continued beyond the acute presentation. (See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"</a>.)</p><p class="headingAnchor" id="H26234520"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Imaging studies generally are performed in patients with significant abdominal symptoms. Plain abdominal radiography may demonstrate dilated loops of bowel consistent with decreased intestinal motility. Abdominal ultrasonography can detect increased bowel wall thickness, hematomas, peritoneal fluid, and intussusception [<a href="#rid17">17,73,74</a>].</p><p>If intussusception is considered, ultrasonography rather than contrast enemas should be the initial screening test. Ileoileal intussusception is seen in more than one-half of the cases of intussusception in patients with IgAV. Contrast enemas, usually indicated in children with signs of an intussusception, neither detect nor help reduce ileoileal intussusception. (See  <a class="medical medical_review" href="/d/html/5898.html" rel="external">"Intussusception in children"</a>.)</p><p>In males who present with scrotal symptoms, Doppler flow studies and/or radionuclide scans can distinguish scrotal pain caused by IgAV from testicular torsion. These studies demonstrate decreased blood flow to the testicle in testicular torsion, but testicular blood flow is normal or increased in males with IgAV. (See <a class="local">'Urologic'</a> above and  <a class="medical medical_review" href="/d/html/6446.html" rel="external">"Causes of scrotal pain in children and adolescents", section on 'Testicular torsion'</a>.)</p><p class="headingAnchor" id="H4032815362"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83077.html" rel="external">"Patient education: IgA vasculitis (Henoch-Schönlein purpura) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/579.html" rel="external">"Patient education: Vasculitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> –<strong> </strong>Immunoglobulin A vasculitis (IgAV), formerly called Henoch-Schönlein purpura (HSP), is the most common systemic vasculitis of childhood. IgAV occurs primarily between the ages of 3 and 15 years. The annual incidence is 10 to 20 per 100,000 in children &lt;17 years of age, with a peak incidence in children between four to six years of age. Approximately 10 percent of IgAV cases occur in adults. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The underlying cause of IgAV is unknown. It is thought that IgAV represents an immune-mediated vasculitis that may be triggered by a variety of antigens, which may include various infections or other environmental exposures. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – IgAV is a self-limited disease and is characterized by a tetrad of clinical manifestations that vary in their occurrence and order of presentation (see <a class="local">'Clinical manifestations in children'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palpable purpura without thrombocytopenia and coagulopathy  (<a class="graphic graphic_picture graphicRef100110 graphicRef119923 graphicRef134597 graphicRef134598 graphicRef134599" href="/d/graphic/100110.html" rel="external">picture 2A-E</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Arthralgia and/or arthritis</p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Kidney disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of IgAV is usually based upon clinical manifestations of the disease  (<a class="graphic graphic_algorithm graphicRef140304" href="/d/graphic/140304.html" rel="external">algorithm 1</a>). There are no diagnostic laboratory tests for IgAV. In patients with an incomplete or unusual presentation, biopsy of the affected organ (eg, skin or kidney) demonstrating predominantly IgA deposition supports the diagnosis of IgAV. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The diagnosis is more difficult if there is an incomplete presentation of IgAV or if the skin manifestations are absent at disease onset. In these circumstances, other causes for purpura, arthritis, abdominal pain, and kidney disease must be considered. Patients in whom the diagnosis is at all in doubt should have a complete blood count, prothrombin time (PT), and urinalysis. The presence of thrombocytopenia or a coagulopathy largely excludes the diagnosis of IgAV. (See <a class="local">'Differential diagnosis'</a> above and <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation</strong> – A urinalysis is performed in all patients diagnosed with IgAV. A serum creatinine level should be obtained in children with hypertension or an abnormal urinalysis. Serum creatinine should be assayed in all adult patients with IgAV because of the increased risk of significant kidney disease. Imaging studies are performed in those with significant gastrointestinal symptoms. Abdominal ultrasonography is indicated in patients with severe abdominal pain. It can detect increased bowel wall thickness, hematomas, peritoneal fluid, and intussusception. Contrast studies may miss intussusception in patients with IgAV. (See <a class="local">'Additional evaluation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.</a></li><li><a class="nounderline abstract_t">Leung AKC, Barankin B, Leong KF. Henoch-Schönlein Purpura in Children: An Updated Review. Curr Pediatr Rev 2020; 16:265.</a></li><li><a class="nounderline abstract_t">Oni L, Sampath S. Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps. Front Pediatr 2019; 7:257.</a></li><li><a class="nounderline abstract_t">Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol 2013; 25:171.</a></li><li><a class="nounderline abstract_t">Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197.</a></li><li><a class="nounderline abstract_t">Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan. Rheumatology (Oxford) 2005; 44:618.</a></li><li><a class="nounderline abstract_t">Dolezalová P, Telekesová P, Nemcová D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31:2295.</a></li><li><a class="nounderline abstract_t">Piram M, Maldini C, Biscardi S, et al. Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study. Rheumatology (Oxford) 2017; 56:1358.</a></li><li><a class="nounderline abstract_t">Shim JO, Han K, Park S, et al. Ten-year Nationwide Population-based Survey on the Characteristics of Children with Henoch-Schӧnlein Purpura in Korea. J Korean Med Sci 2018; 33:e174.</a></li><li><a class="nounderline abstract_t">Rhim JW, Lee YT, Kang HM, et al. Changes in clinical features in Henoch-Schönlein purpura during three decades: an observational study at a single hospital in Korea. Clin Rheumatol 2019; 38:2811.</a></li><li><a class="nounderline abstract_t">Blanco R, Martínez-Taboada VM, Rodríguez-Valverde V, et al. Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum 1997; 40:859.</a></li><li><a class="nounderline abstract_t">Hočevar A, Rotar Z, Ostrovršnik J, et al. Incidence of IgA vasculitis in the adult Slovenian population. Br J Dermatol 2014; 171:524.</a></li><li><a class="nounderline abstract_t">Calvo-Río V, Loricera J, Mata C, et al. Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore) 2014; 93:106.</a></li><li><a class="nounderline abstract_t">Kang Y, Park JS, Ha YJ, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura. J Korean Med Sci 2014; 29:198.</a></li><li><a class="nounderline abstract_t">Batu ED, Sarı A, Erden A, et al. Comparing immunoglobulin A vasculitis (Henoch-Schönlein purpura) in children and adults: a single-centre study from Turkey. Scand J Rheumatol 2018; 47:481.</a></li><li><a class="nounderline abstract_t">Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35:143.</a></li><li><a class="nounderline abstract_t">Calviño MC, Llorca J, García-Porrúa C, et al. Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 2001; 80:279.</a></li><li><a class="nounderline abstract_t">Hwang HH, Lim IS, Choi BS, Yi DY. Analysis of seasonal tendencies in pediatric Henoch-Schönlein purpura and comparison with outbreak of infectious diseases. Medicine (Baltimore) 2018; 97:e12217.</a></li><li><a class="nounderline abstract_t">Atkinson SR, Barker DJ. Seasonal distribution of Henoch-Schönlein purpura. Br J Prev Soc Med 1976; 30:22.</a></li><li><a class="nounderline abstract_t">Levy M, Broyer M, Arsan A, et al. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 1976; 6:183.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Epidemiology of Henoch-Schönlein purpura. Cleve Clin J Med 2002; 69 Suppl 2:SII87.</a></li><li><a class="nounderline abstract_t">Bonetto C, Trotta F, Felicetti P, et al. Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine 2016; 34:6641.</a></li><li><a class="nounderline abstract_t">Woerner A, Rudin C, Bonetto C, et al. IgA vasculitis (Henoch-Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine 2017; 35:1559.</a></li><li><a class="nounderline abstract_t">Piram M, Gonzalez Chiappe S, Madhi F, et al. Vaccination and Risk of Childhood IgA Vasculitis. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Bayram C, Demircin G, Erdoğan O, et al. Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura. Acta Paediatr 2011; 100:745.</a></li><li><a class="nounderline abstract_t">Dillon MJ. Henoch-Schönlein purpura: recent advances. Clin Exp Rheumatol 2007; 25:S66.</a></li><li><a class="nounderline abstract_t">Ekinci RMK, Balci S, Bisgin A, et al. MEFV gene variants in children with Henoch-Schönlein purpura and association with clinical manifestations: a single-center Mediterranean experience. Postgrad Med 2019; 131:68.</a></li><li><a class="nounderline abstract_t">Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum 1990; 33:1114.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108.</a></li><li><a class="nounderline abstract_t">Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936.</a></li><li><a class="nounderline abstract_t">Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798.</a></li><li><a class="nounderline abstract_t">Rigante D, Castellazzi L, Bosco A, Esposito S. Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura? Autoimmun Rev 2013; 12:1016.</a></li><li><a class="nounderline abstract_t">Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schönlein purpura: an updated review. Autoimmun Rev 2014; 13:355.</a></li><li><a class="nounderline abstract_t">Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health 2013; 49:995.</a></li><li><a class="nounderline abstract_t">López-Mejías R, Genre F, Pérez BS, et al. Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Res Ther 2015; 17:102.</a></li><li><a class="nounderline abstract_t">Jiang J, Duan W, Shang X, et al. Inducible nitric oxide synthase gene polymorphisms are associated with a risk of nephritis in Henoch-Schönlein purpura children. Eur J Pediatr 2017; 176:1035.</a></li><li><a class="nounderline abstract_t">Zhang X, Wu L, Chai M, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Henoch-Schönlein purpura: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2019; 20:1470320319836302.</a></li><li><a class="nounderline abstract_t">Da Dalt L, Zerbinati C, Strafella MS, et al. Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study. Ital J Pediatr 2016; 42:60.</a></li><li><a class="nounderline abstract_t">Urushikubo J, Yanai S, Nakamura S, et al. IgA vasculitis in a patient with ulcerative colitis under infliximab: drug-induced or genetic? Clin J Gastroenterol 2021; 14:198.</a></li><li><a class="nounderline abstract_t">Perkovic D, Simac P, Katic J. IgA vasculitis during secukinumab therapy. Clin Rheumatol 2021; 40:2071.</a></li><li><a class="nounderline abstract_t">Yang YH, Huang MT, Lin SC, et al. Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. Clin Exp Immunol 2000; 122:285.</a></li><li><a class="nounderline abstract_t">Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics 1971; 47:1023.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schönlein purpura. J Rheumatol 1997; 24:2246.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura. Arthritis Rheum 1992; 35:1377.</a></li><li><a class="nounderline abstract_t">Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 2007; 22:2067.</a></li><li><a class="nounderline abstract_t">Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.</a></li><li><a class="nounderline abstract_t">Lau KK, Suzuki H, Novak J, Wyatt RJ. Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol 2010; 25:19.</a></li><li><a class="nounderline abstract_t">Kawakami T, Watabe H, Mizoguchi M, Soma Y. Elevated serum IgA anticardiolipin antibody levels in adult Henoch-Schönlein purpura. Br J Dermatol 2006; 155:983.</a></li><li><a class="nounderline abstract_t">Burden AD, Gibson IW, Rodger RS, Tillman DM. IgA anticardiolipin antibodies associated with Henoch-Schönlein purpura. J Am Acad Dermatol 1994; 31:857.</a></li><li><a class="nounderline abstract_t">Yang YH, Chang CJ, Chuang YH, et al. Identification and characterization of IgA antibodies against β2-glycoprotein I in childhood Henoch-Schönlein purpura. Br J Dermatol 2012; 167:874.</a></li><li><a class="nounderline abstract_t">Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev 2017; 16:1246.</a></li><li><a class="nounderline abstract_t">Imai T, Nishiyama K, Ueki K, et al. Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schönlein purpura nephritis. Clin Transl Immunology 2020; 9:e1212.</a></li><li><a class="nounderline abstract_t">Ghrahani R, Ledika MA, Sapartini G, Setiabudiawan B. Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura. Asia Pac Allergy 2014; 4:42.</a></li><li><a class="nounderline abstract_t">Peru H, Soylemezoglu O, Bakkaloglu SA, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008; 27:1087.</a></li><li><a class="nounderline abstract_t">Çakıcı EK, Gür G, Yazılıtaş F, et al. A retrospective analysis of children with Henoch-Schonlein purpura and re-evaluation of renal pathologies using Oxford classification. Clin Exp Nephrol 2019; 23:939.</a></li><li><a class="nounderline abstract_t">Gómez S, Pérez M, Pellegrini M, et al. Henoch-Schonlein purpura in pediatrics: Ten years of experience at a moderate risk office of a general hospital. Arch Argent Pediatr 2020; 118:31.</a></li><li><a class="nounderline abstract_t">Liao CH, Tsai M, Yang YH, et al. Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study. Pediatr Rheumatol Online J 2020; 18:86.</a></li><li><a class="nounderline abstract_t">Jauhola O, Ronkainen J, Koskimies O, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 2010; 95:871.</a></li><li><a class="nounderline abstract_t">Peeters V, De Raeve L. Blistering eruptions in Henoch-Schönlein syndrome: more common than assumed. Eur J Pediatr 2018; 177:475.</a></li><li><a class="nounderline abstract_t">Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Schönlein purpura: a review of 261 patients. Acta Paediatr 2004; 93:1427.</a></li><li><a class="nounderline abstract_t">FELDT RH, STICKLER GB. The gastrointestinal manifestations of anaphylactoid purpura in children. Proc Staff Meet Mayo Clin 1962; 37:465.</a></li><li><a class="nounderline abstract_t">Wu CS, Tung SY. Henoch-Schönlein purpura complicated by upper gastrointestinal bleeding with an unusual endoscopic picture. J Clin Gastroenterol 1994; 19:128.</a></li><li><a class="nounderline abstract_t">Nathan K, Gunasekaran TS, Berman JH. Recurrent gastrointestinal Henoch-Schönlein purpura. J Clin Gastroenterol 1999; 29:86.</a></li><li><a class="nounderline abstract_t">Gunasekaran TS, Berman J, Gonzalez M. Duodenojejunitis: is it idiopathic or is it Henoch-Schönlein purpura without the purpura? J Pediatr Gastroenterol Nutr 2000; 30:22.</a></li><li><a class="nounderline abstract_t">Johnson EF, Lehman JS, Wetter DA, et al. Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol 2015; 172:1358.</a></li><li><a class="nounderline abstract_t">Li B, Ren Q, Ling J, et al. Clinical relevance of neutrophil-to-lymphocyte ratio and mean platelet volume in pediatric Henoch-Schonlein Purpura: a meta-analysis. Bioengineered 2021; 12:286.</a></li><li><a class="nounderline abstract_t">Lévy-Weil FE, Sigal M, Renard P, et al. [Acute pancreatitis in rheumatoid purpura. Apropos of 2 cases]. Rev Med Interne 1997; 18:54.</a></li><li><a class="nounderline abstract_t">Cheung KM, Mok F, Lam P, Chan KH. Pancreatitis associated with Henoch-Schonlein purpura. J Paediatr Child Health 2001; 37:311.</a></li><li><a class="nounderline abstract_t">Amemoto K, Nagita A, Aoki S, et al. Ultrasonographic gallbladder wall thickening in children with Henoch-Schonlein purpura. J Pediatr Gastroenterol Nutr 1994; 19:126.</a></li><li><a class="nounderline abstract_t">Branski D, Gross V, Gross-Kieselstein E, et al. Pancreatitis as a complication of Henoch--Schonlein purpura. J Pediatr Gastroenterol Nutr 1982; 1:275.</a></li><li><a class="nounderline abstract_t">Kumon Y, Hisatake K, Chikamori M, et al. A case of vasculitic cholecystitis associated with Schönlein-Henoch purpura in an adult. Gastroenterol Jpn 1988; 23:68.</a></li><li><a class="nounderline abstract_t">Cho CS, Min JK, Park SH, et al. Protein losing enteropathy associated with Henoch-Schönlein purpura in a patient with rheumatoid arthritis. Scand J Rheumatol 1996; 25:334.</a></li><li><a class="nounderline abstract_t">Choong CK, Beasley SW. Intra-abdominal manifestations of Henoch-Schönlein purpura. J Paediatr Child Health 1998; 34:405.</a></li><li><a class="nounderline abstract_t">Schwab J, Benya E, Lin R, Majd K. Contrast enema in children with Henoch-Schönlein purpura. J Pediatr Surg 2005; 40:1221.</a></li><li><a class="nounderline abstract_t">Chan H, Tang YL, Lv XH, et al. Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis. PLoS One 2016; 11:e0167346.</a></li><li><a class="nounderline abstract_t">Wang K, Sun X, Cao Y, et al. Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: A retrospective study. Medicine (Baltimore) 2018; 97:e12520.</a></li><li><a class="nounderline abstract_t">Buscatti IM, Casella BB, Aikawa NE, et al. Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol 2018; 37:1319.</a></li><li><a class="nounderline abstract_t">Dalpiaz A, Schwamb R, Miao Y, et al. Urological Manifestations of Henoch-Schonlein Purpura: A Review. Curr Urol 2015; 8:66.</a></li><li><a class="nounderline abstract_t">Balslev T. [Schoenlein-Henoch syndrome with acute scrotal condition simulating torsion of the testis]. Ugeskr Laeger 1990; 152:678.</a></li><li><a class="nounderline abstract_t">Chamberlain RS, Greenberg LW. Scrotal involvement in Henoch-Schönlein purpura: a case report and review of the literature. Pediatr Emerg Care 1992; 8:213.</a></li><li><a class="nounderline abstract_t">Søreide K. Surgical management of nonrenal genitourinary manifestations in children with Henoch-Schönlein purpura. J Pediatr Surg 2005; 40:1243.</a></li><li><a class="nounderline abstract_t">Buscatti IM, Abrão HM, Kozu K, et al. Characterization of scrotal involvement in children and adolescents with IgA vasculitis. Adv Rheumatol 2018; 58:38.</a></li><li><a class="nounderline abstract_t">Verim L, Cebeci F, Erdem MR, Somay A. Henoch-Schönlein purpura without systemic involvement beginning with acute scrotum and mimicking torsion of testis. Arch Ital Urol Androl 2013; 85:50.</a></li><li><a class="nounderline abstract_t">Ha TS, Lee JS. Scrotal involvement in childhood Henoch-Schönlein purpura. Acta Paediatr 2007; 96:552.</a></li><li><a class="nounderline abstract_t">Belman AL, Leicher CR, Moshé SL, Mezey AP. Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature. Pediatrics 1985; 75:687.</a></li><li><a class="nounderline abstract_t">Misra AK, Biswas A, Das SK, et al. Henoch-Schonlein purpura with intracerebral haemorrhage. J Assoc Physicians India 2004; 52:833.</a></li><li><a class="nounderline abstract_t">Bulun A, Topaloglu R, Duzova A, et al. Ataxia and peripheral neuropathy: rare manifestations in Henoch-Schönlein purpura. Pediatr Nephrol 2001; 16:1139.</a></li><li><a class="nounderline abstract_t">Stefek B, Beck M, Ioffreda M, et al. Henoch-Schönlein Purpura with Posterior Reversible Encephalopathy Syndrome. J Pediatr 2015; 167:1152.</a></li><li><a class="nounderline abstract_t">Chaussain M, de Boissieu D, Kalifa G, et al. Impairment of lung diffusion capacity in Schönlein-Henoch purpura. J Pediatr 1992; 121:12.</a></li><li><a class="nounderline abstract_t">Cazzato S, Bernardi F, Cinti C, et al. Pulmonary function abnormalities in children with Henoch-Schönlein purpura. Eur Respir J 1999; 13:597.</a></li><li><a class="nounderline abstract_t">Nadrous HF, Yu AC, Specks U, Ryu JH. Pulmonary involvement in Henoch-Schönlein purpura. Mayo Clin Proc 2004; 79:1151.</a></li><li><a class="nounderline abstract_t">Vats KR, Vats A, Kim Y, et al. Henoch-Schönlein purpura and pulmonary hemorrhage: a report and literature review. Pediatr Nephrol 1999; 13:530.</a></li><li><a class="nounderline abstract_t">Olson JC, Kelly KJ, Pan CG, Wortmann DW. Pulmonary disease with hemorrhage in Henoch-Schöenlein purpura. Pediatrics 1992; 89:1177.</a></li><li><a class="nounderline abstract_t">Besbas N, Duzova A, Topaloglu R, et al. Pulmonary haemorrhage in a 6-year-old boy with Henoch-Schönlein purpura. Clin Rheumatol 2001; 20:293.</a></li><li><a class="nounderline abstract_t">Di Pietro GM, Castellazzi ML, Mastrangelo A, et al. Henoch-Schönlein Purpura in children: not only kidney but also lung. Pediatr Rheumatol Online J 2019; 17:75.</a></li><li><a class="nounderline abstract_t">Muqit MM, Gallagher MJ, Gavin M, et al. Henoch-Schonlein purpura with keratitis and granulomatous anterior uveitis. Br J Ophthalmol 2005; 89:1221.</a></li><li><a class="nounderline abstract_t">Chalhoub NE, Kaw D, Nagaraja V. A Man With a Nonblanchable Purpuric Rash. JAMA 2017; 317:2329.</a></li><li><a class="nounderline abstract_t">Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13:1271.</a></li><li><a class="nounderline abstract_t">Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis Rheumatol 2017; 69:1862.</a></li><li><a class="nounderline abstract_t">Hong S, Ahn SM, Lim DH, et al. Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes. Clin Exp Rheumatol 2016; 34:S77.</a></li><li><a class="nounderline abstract_t">Komatsu H, Fujimoto S, Maruyama S, et al. Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR). PLoS One 2018; 13:e0196955.</a></li><li><a class="nounderline abstract_t">Villatoro-Villar M, Crowson CS, Warrington KJ, et al. Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: A Retrospective Cohort Study. Mayo Clin Proc 2019; 94:1769.</a></li><li><a class="nounderline abstract_t">Gupta V, Aggarwal A, Gupta R, et al. Differences between adult and pediatric onset Henoch-Schonlein purpura from North India. Int J Rheum Dis 2018; 21:292.</a></li><li><a class="nounderline abstract_t">Poterucha TJ, Wetter DA, Gibson LE, et al. Histopathology and correlates of systemic disease in adult Henoch-Schönlein purpura: a retrospective study of microscopic and clinical findings in 68 patients at Mayo Clinic. J Am Acad Dermatol 2013; 68:420.</a></li><li><a class="nounderline abstract_t">Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Henoch-Schönlein purpura associated with solid-organ malignancies: three case reports and a literature review. Acta Derm Venereol 2012; 92:388.</a></li><li><a class="nounderline abstract_t">Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int 2001; 59:823.</a></li><li><a class="nounderline abstract_t">Lin Q, Min Y, Li Y, et al. Henoch-Schönlein purpura with hypocomplementemia. Pediatr Nephrol 2012; 27:801.</a></li><li><a class="nounderline abstract_t">McCarthy HJ, Tizard EJ. Clinical practice: Diagnosis and management of Henoch-Schönlein purpura. Eur J Pediatr 2010; 169:643.</a></li><li><a class="nounderline abstract_t">Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 2019; 58:1607.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.</a></li><li><a class="nounderline abstract_t">Fang Y, Peng K, Zhao H, Chen J. The characteristics of video capsule endoscopy in pediatric Henoch-Schönlein purpura with gastrointestinal symptoms. Pediatr Rheumatol Online J 2020; 18:84.</a></li><li><a class="nounderline abstract_t">Saraclar Y, Tinaztepe K, Adalioğlu G, Tuncer A. Acute hemorrhagic edema of infancy (AHEI)--a variant of Henoch-Schönlein purpura or a distinct clinical entity? J Allergy Clin Immunol 1990; 86:473.</a></li><li><a class="nounderline abstract_t">Caksen H, Odabaş D, Kösem M, et al. Report of eight infants with acute infantile hemorrhagic edema and review of the literature. J Dermatol 2002; 29:290.</a></li><li><a class="nounderline abstract_t">Krause I, Lazarov A, Rachmel A, et al. Acute haemorrhagic oedema of infancy, a benign variant of leucocytoclastic vasculitis. Acta Paediatr 1996; 85:114.</a></li><li><a class="nounderline abstract_t">Parker L, Shahar-Nissan K, Ashkenazi-Hoffnung L, et al. Acute hemorrhagic edema of infancy: the experience of a large tertiary pediatric center in Israel. World J Pediatr 2017; 13:341.</a></li><li><a class="nounderline abstract_t">Pittet LF, Siebert JN, Lacroix LE. Striking but benign: acute haemorrhagic oedema of infancy. Lancet 2022; 399:e41.</a></li><li><a class="nounderline abstract_t">Watanabe T, Sato Y. Renal involvement and hypocomplementemia in a patient with acute hemorrhagic edema of infancy. Pediatr Nephrol 2007; 22:1979.</a></li><li><a class="nounderline abstract_t">Yu JE, Mancini AJ, Miller ML. Intussusception in an infant with acute hemorrhagic edema of infancy. Pediatr Dermatol 2007; 24:61.</a></li></ol></div><div id="topicVersionRevision">Topic 6406 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32384035" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Henoch-Schönlein Purpura in Children: An Updated Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31316952" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23318735" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401245" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15671050" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517648" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444335" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29915525" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ten-year Nationwide Population-based Survey on the Characteristics of Children with Henoch-Schӧnlein Purpura in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31209707" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changes in clinical features in Henoch-Schönlein purpura during three decades: an observational study at a single hospital in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153547" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Henoch-Schönlein purpura in adulthood and childhood: two different expressions of the same syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24601900" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Incidence of IgA vasculitis in the adult Slovenian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646467" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24550645" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912602" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparing immunoglobulin A vasculitis (Henoch-Schönlein purpura) in children and adults: a single-centre study from Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16325655" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11552081" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30200139" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Analysis of seasonal tendencies in pediatric Henoch-Schönlein purpura and comparison with outbreak of infectious diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/949569" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Seasonal distribution of Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/139081" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anaphylactoid purpura nephritis in childhood: natural history and immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086273" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epidemiology of Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398442" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vasculitis as an adverse event following immunization - Systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28034474" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : IgA vasculitis (Henoch-Schönlein): Case definition andguidelines for data collection, analysis, and presentation of immunisation safety data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30377240" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vaccination and Risk of Childhood IgA Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21231959" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence of MEFV gene mutations and their clinical correlations in Turkish children with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17428373" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Henoch-Schönlein purpura: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30513227" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : MEFV gene variants in children with Henoch-Schönlein purpura and association with clinical manifestations: a single-center Mediterranean experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202310" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202309" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322081" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413568" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684700" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24424188" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The diagnosis and classification of Henoch-Schönlein purpura: an updated review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24134307" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Henoch-Schönlein purpura in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25889603" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28593405" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inducible nitric oxide synthase gene polymorphisms are associated with a risk of nephritis in Henoch-Schönlein purpura children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30854921" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to Henoch-Schönlein purpura: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27316345" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Henoch-Schönlein purpura and drug and vaccine use in childhood: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33141395" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : IgA vasculitis in a patient with ulcerative colitis under infliximab: drug-induced or genetic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860543" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : IgA vasculitis during secukinumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091287" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5003905" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Elevated serum IgA globulin in anaphylactoid purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375892" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Alterations in the O-linked glycosylation of IgA1 in children with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1445457" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943324" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10575422" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19526254" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pathogenesis of Henoch-Schönlein purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034529" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Elevated serum IgA anticardiolipin antibody levels in adult Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962736" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : IgA anticardiolipin antibodies associated with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632612" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Identification and characterization of IgA antibodies againstβ2-glycoprotein I in childhood Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037908" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33282293" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Involvement of activated cytotoxic T lymphocytes and natural killer cells in Henoch-Schönlein purpura nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24527410" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Age of onset as a risk factor of renal involvement in Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305976" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30895528" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A retrospective analysis of children with Henoch-Schonlein purpura and re-evaluation of renal pathologies using Oxford classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31984693" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Henoch-Schonlein purpura in pediatrics: Ten years of experience at a moderate risk office of a general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33172497" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371584" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28812140" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Blistering eruptions in Henoch-Schönlein syndrome: more common than assumed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15513566" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gastrointestinal manifestations in Henoch-Schönlein purpura: a review of 261 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13892165" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The gastrointestinal manifestations of anaphylactoid purpura in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7963359" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Henoch-Schönlein purpura complicated by upper gastrointestinal bleeding with an unusual endoscopic picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405241" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrent gastrointestinal Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10630435" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Duodenojejunitis: is it idiopathic or is it Henoch-Schönlein purpura without the purpura?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308217" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Henoch-Schönlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33412982" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical relevance of neutrophil-to-lymphocyte ratio and mean platelet volume in pediatric Henoch-Schonlein Purpura: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9092019" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [Acute pancreatitis in rheumatoid purpura. Apropos of 2 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11468053" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pancreatitis associated with Henoch-Schonlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965465" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ultrasonographic gallbladder wall thickening in children with Henoch-Schonlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7186039" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pancreatitis as a complication of Henoch--Schonlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3350280" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A case of vasculitic cholecystitis associated with Schönlein-Henoch purpura in an adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921929" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Protein losing enteropathy associated with Henoch-Schönlein purpura in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767498" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intra-abdominal manifestations of Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080921" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Contrast enema in children with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902749" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30235770" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch-Schönlein purpura: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330742" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889120" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Urological Manifestations of Henoch-Schonlein Purpura: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2321285" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : [Schoenlein-Henoch syndrome with acute scrotal condition simulating torsion of the testis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1513732" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Scrotal involvement in Henoch-Schönlein purpura: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080926" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Surgical management of nonrenal genitourinary manifestations in children with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657092" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Characterization of scrotal involvement in children and adolescents with IgA vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23695408" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Henoch-Schönlein purpura without systemic involvement beginning with acute scrotum and mimicking torsion of testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306010" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Scrotal involvement in childhood Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2984637" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909863" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Henoch-Schonlein purpura with intracerebral haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11793117" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ataxia and peripheral neuropathy: rare manifestations in Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26323197" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Henoch-Schönlein Purpura with Posterior Reversible Encephalopathy Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1625069" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Impairment of lung diffusion capacity in Schönlein-Henoch purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232432" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pulmonary function abnormalities in children with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15357037" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pulmonary involvement in Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452284" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Henoch-Schönlein purpura and pulmonary hemorrhage: a report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594373" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pulmonary disease with hemorrhage in Henoch-Schöenlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11529643" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pulmonary haemorrhage in a 6-year-old boy with Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752918" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Henoch-Schönlein Purpura in children: not only kidney but also lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113386" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Henoch-Schonlein purpura with keratitis and granulomatous anterior uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609516" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A Man With a Nonblanchable Purpuric Rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961015" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Henoch-Schönlein Purpura in adults: outcome and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605168" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26842218" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Late-onset IgA vasculitis in adult patients exhibits distinct clinical characteristics and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29738576" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486380" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29115055" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Differences between adult and pediatric onset Henoch-Schonlein purpura from North India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22959233" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Histopathology and correlates of systemic disease in adult Henoch-Schönlein purpura: a retrospective study of microscopic and clinical findings in 68 patients at Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22293661" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Henoch-Schönlein purpura associated with solid-organ malignancies: three case reports and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231337" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271365" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Henoch-Schönlein purpura with hypocomplementemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20012647" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical practice: Diagnosis and management of Henoch-Schönlein purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879080" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366584" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33115491" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The characteristics of video capsule endoscopy in pediatric Henoch-Schönlein purpura with gastrointestinal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229809" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acute hemorrhagic edema of infancy (AHEI)--a variant of Henoch-Schönlein purpura or a distinct clinical entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081160" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Report of eight infants with acute infantile hemorrhagic edema and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834993" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute haemorrhagic oedema of infancy, a benign variant of leucocytoclastic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28470578" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Acute hemorrhagic edema of infancy: the experience of a large tertiary pediatric center in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26411985" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Striking but benign: acute haemorrhagic oedema of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17704952" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Renal involvement and hypocomplementemia in a patient with acute hemorrhagic edema of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300653" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intussusception in an infant with acute hemorrhagic edema of infancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
